BeiGene
- Membership Level
- Diamond
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,000+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market an internally-discovered product, BRUKINSA® (zanubrutinib) in the United States. To learn more about BeiGene, visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
BeiGene: Blood Cancer Has No Borders, Neither Do We: https://youtu.be/UUoKZYigazk
More information:
- Prescribing Information
- Dosing and Administration
- Patient Support
- Learn More about BeiGene
- BeiGene Corporate Brochure
- Brukinsa Branded HCP CVA
- Brukinsa Patient Brochure
- Dosing and Administration Guide
- Large Format PI (Digital) PDF
- myBeiGene and AssistPoint
- myBeiGene Enrollment Form
- myBeiGene HCP Brochure
- myBeiGene ONA Bio Sheet
- myBeiGene Patient Brochure
- NCCN Guidelines B-Cell Lymphomas MCL Flashcard
- Ordering Info and Distributor Sheet
Click the link to view BeiGene’s activities and presentations presented this year during the 25th European Hematology Association (EHA) Virtual Congress that took place on June 11-14. http://ir.beigene.com/news-
